https://m2.mtmt.hu/ hun 2026-09-22 22:40 JournalArticle 36410412 VALIDATED true Essmat, N. and Boldizsár, I., Jr. authors contributed equally to this work. 0 false 2026-09-07T07:54:35.882+0000 2026-07-10T07:30:29.243+0000 2025-10-31T13:12:06.553+0000 true 10015206 Áncsán Gizella /api/admin/10015206 Admin Áncsán Gizella (SE admin) true 10015206 2026-09-07T07:53:09.113+0000 2026-09-07T07:53:09.113+0000 2026-01-21T11:15:01.744+0000 true 10015546 Berhidi Anna /api/admin/10015546 Admin Berhidi Anna (SE_KK_Admin5_BA, admin) true 10015546 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 1134514 Survey paper true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/1134514 Összefoglaló cikk SubType Összefoglaló cikk (Folyóiratcikk) 102 true 1134514 true 1 /api/category/1 Category Tudományos true 1 Essmat, Nariman true true /api/journal/10003252 REVIEWED INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 true false 10003252 false 10003252 true 1661-6596 1422-0067 Journal FOREIGN 26 21 10526 10526 34 2025 The current pharmacological approach for the treatment of opioid use disorder (OUD), as a result of prescription misuse or illicit opioids, utilises opioid ligands that have either an agonist or antagonist profile. In this context, methadone and buprenorphine act as opioid agonists, whereas naltrexone functions as an opioid antagonist. To decrease the reinforcing effects of illicit opioids, higher doses of methadone and buprenorphine have been recommended, but this is associated with increased side effects. Therefore, several preclinical efforts have been carried out over the last decades to find drugs that act on receptors other than opioid receptors. A large body of preclinical evidence has shown the ability of N-methyl-D-aspartate receptor (NMDAR) antagonists like ketamine to treat opioid addiction behaviours in animals. Indeed, ketamine by itself is an addictive drug; thus, the treatment of OUD is still a matter to be solved. Growing data position glycine transporter 1 as a possible therapeutic target for the treatment of substance use disorder. This transporter regulates the reuptake of glycine, which can modulate the function of both NMDARs and GPR158, a metabotropic glycine receptor (mGlyR); thus, it is worth investigating in the management of OUD. To gain insight into the role of glycinergic transmission in OUD, alongside NMDAR-mediated glutamatergic transmission, dopaminergic and GABAergic transmission were also reviewed. Funding 2063415 /api/funding/2063415 (FK_138389) false true Funding 2063416 /api/funding/2063416 (TKP2021-EGA-25) false true Funding 2063417 /api/funding/2063417 (Semmelweis 250+ Kiválósági PhD Ösztöndíj) false true Funding 2063418 /api/funding/2063418 (2024-2.1.1-EKÖP) false true true true 2025 true true true false true false GOLD 2026-09-07 true https://doi.org/10.3390/ijms262110526 1 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 1 1 1 1 0 8 8 Folyóiratcikk Journal Article 24 1 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2026 0 1 1 1 1 D1 false false false false 2025-11-24T10:02:09.067+0000 Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); Gyógyszerhatástani Intézet (SE / GYTK) 14 33 3 14 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 128338044 /api/authorship/128338044 Essmat, Nariman [Gomaa, Nariman Essmat Mohamed Abdeltawab (In vivo and in vi...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 1 0.071 true false false Author 10090082 /api/author/10090082 Gomaa Nariman Essmat Mohamed Abdeltawab (In vivo and in vitro pain assessment) Gomaa Nariman Essmat Mohamed Abdeltawab true true Essmat Nariman true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338045 /api/authorship/128338045 Boldizsár, Imre Jr.* [Boldizsár Jr, Imre (farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 2 0.071 true false false Author 10096971 /api/author/10096971 Boldizsár Jr Imre (farmakológia) Boldizsár Jr Imre true true Boldizsár Imre Jr. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338046 /api/authorship/128338046 Chalabiani, Yashar [Chalabiani, Yashar (neuropsychopharma...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 3 0.071 false false false Author 10101816 /api/author/10101816 Chalabiani Yashar (neuropsychopharmacology) Chalabiani Yashar true true Chalabiani Yashar true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338047 /api/authorship/128338047 Varga, Bence Tamás [Varga, Bence Tamás (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 4 0.071 false false false Author 10075565 /api/author/10075565 Varga Bence Tamás (Farmakológia) Varga Bence Tamás true true Varga Bence Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338048 /api/authorship/128338048 Abbood, Sarah Kadhim [Abbood, Sarah Kadhim (In vivo AND In vi...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 5 0.071 false false false Author 10090125 /api/author/10090125 Abbood Sarah Kadhim (In vivo AND In vitro pain assessment) Abbood Sarah Kadhim true true Abbood Sarah Kadhim true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338049 /api/authorship/128338049 Kirchlechner-Farkas, Judit Mária [Kirchlechner-Farkas, Judit Mária (famakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 6 0.071 false false false Author 10101715 /api/author/10101715 Kirchlechner-Farkas Judit Mária (famakológia) Kirchlechner-Farkas Judit Mária true true Kirchlechner-Farkas Judit Mária true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338050 /api/authorship/128338050 Király, Kornél [Király, Kornél P (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 7 0.071 false false false Author 10015480 /api/author/10015480 Király Kornél P (Farmakológia) Király Kornél P true 10015480 true Király Kornél true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338051 /api/authorship/128338051 Miklya, Ildikó [Miklya, Ildikó (Neuropszichofarma...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 8 0.071 false false false Author 10011448 /api/author/10011448 Miklya Ildikó (Neuropszichofarmakológia) Miklya Ildikó true 10011448 true Miklya Ildikó true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338052 /api/authorship/128338052 Gyertyán, István [Gyertyán, István (Viselkedésfarmako...), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 9 0.071 false false false Author 10009109 /api/author/10009109 Gyertyán István (Viselkedésfarmakológia) Gyertyán István true 10009109 true Gyertyán István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338053 /api/authorship/128338053 Tábi, Tamás [Tábi, Tamás (Farmakológia), szerző] Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE); Gyógyszerhatástani Intézet (SE / GYTK) 10 0.071 false false false Author 10012548 /api/author/10012548 Tábi Tamás (Farmakológia) Tábi Tamás true 10012548 true Tábi Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338054 /api/authorship/128338054 Fürst, Susanna [Fürst, Zsuzsanna (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 11 0.071 false false false Author 10005121 /api/author/10005121 Fürst Zsuzsanna (Farmakológia) Fürst Zsuzsanna true 10005121 true Fürst Susanna true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338055 /api/authorship/128338055 Harsing, Laszlo G. [Hársing, László Gábor (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 12 0.071 false false false Author 10000022 /api/author/10000022 Hársing László Gábor (Farmakológia) Hársing László Gábor true 10000022 true Harsing Laszlo G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338056 /api/authorship/128338056 Zádor, Ferenc [Zádor, Ferenc (Opioid receptorok), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I) 13 0.071 false false Author 10031135 /api/author/10031135 Zádor Ferenc (Opioid receptorok) Zádor Ferenc true 10031135 true Zádor Ferenc true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 128338057 /api/authorship/128338057 Al-Khrasani, Mahmoud ✉ [Al-Khrasani, Mahmoud (Farmakológia), szerző] Farmakológiai és Farmakoterápiás Intézet (SE / AOK / I); Farmakológiai és Gyógyszerkutatás-fejlesztési K... (SE / KSZE) 14 0.071 false true true Author 10015484 /api/author/10015484 Al-Khrasani Mahmoud (Farmakológia) Al-Khrasani Mahmoud true 10015484 true Al-Khrasani Mahmoud true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 30089590 /api/publicationidentifier/30089590 DOI: 10.3390/ijms262110526 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3390/ijms262110526 https://doi.org/10.3390/ijms262110526 false true PublicationIdentifier 30207513 /api/publicationidentifier/30207513 WoS: 001612716300001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 001612716300001 https://www.webofscience.com/wos/woscc/full-record/001612716300001 false true PublicationIdentifier 30218468 /api/publicationidentifier/30218468 Scopus: 105021632191 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 105021632191 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105021632191 true true PublicationIdentifier 30207512 /api/publicationidentifier/30207512 PubMed: 41226576 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 41226576 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41226576&dopt=Abstract false true Classification 12197 /api/classification/12197 Gyógyszerészet, farmakogenomika, gyógyszerkutatás és tervezés, gyógyszeres kezelés true true SjrRating 11593300 /api/sjrrating/11593300 sjr:D1 (2025) Scopus - Inorganic Chemistry INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 5 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 1604 /api/classificationexternal/1604 Scopus - Inorganic Chemistry true 1604 true D1 DIRECT true true Reference 69493471 /api/reference/69493471 1. 1989: HIV-1 Infection among Intravenous Drug Users in Manhattan, New York City, from 1977 through 1987., J. Am. Med. Assoc., 261, p. 1008, DOI: 10.1001/jama.1989.03420070058030 1 10.1001/jama.1989.03420070058030 false true Reference 69493472 /api/reference/69493472 2. Brownstein 1993: A Brief History of Opiates, Opioid Peptides, and Opioid Receptors., Proc. Natl. Acad. Sci. USA, 90, p. 5391, DOI: 10.1073/pnas.90.12.5391 2 10.1073/pnas.90.12.5391 false true Reference 69493473 /api/reference/69493473 3. Bode 2017: Fentanyl Laced Heroin and Its Contribution to a Spike in Heroin Overdose in Miami-Dade County., Am. J. Emerg. Med., 35, p. 1364, DOI: 10.1016/j.ajem.2017.02.043 3 10.1016/j.ajem.2017.02.043 false true Reference 69493474 /api/reference/69493474 4. Mistler 2021: Engagement in Harm Reduction Strategies After Suspected Fentanyl Contamination Among Opioid-Dependent Individuals., J. Community Health, 46, p. 349, DOI: 10.1007/s10900-020-00928-3 4 10.1007/s10900-020-00928-3 false true Reference 69493475 /api/reference/69493475 5. Yu 2024: Fluorofentanyl and Novel Synthetic Opioids in Accidental Overdose Deaths., J. Anal. Toxicol., 48, p. 573, DOI: 10.1093/jat/bkae062 5 10.1093/jat/bkae062 false true Reference 69493476 /api/reference/69493476 6. Volkow 2021: The Changing Opioid Crisis: Development, Challenges and Opportunities., Mol. Psychiatry, 26, p. 218, DOI: 10.1038/s41380-020-0661-4 6 10.1038/s41380-020-0661-4 false true Reference 69493477 /api/reference/69493477 7. Hosztafi, S., Galambos, A.R., Köteles, I., Karádi, D., Fürst, S., and Al-Khrasani, M. (2024). Opioid-Based Haptens: Development of Immunotherapy. Int. J. Mol. Sci., 25., DOI: 10.3390/ijms25147781 7 10.3390/ijms25147781 false true Reference 69493478 /api/reference/69493478 8. Buresh 2021: Treatment of Opioid Use Disorder in Primary Care., BMJ, 373, p. n784, DOI: 10.1136/bmj.n784 8 10.1136/bmj.n784 false true Reference 69493479 /api/reference/69493479 9. Mattick 2009: Methadone Maintenance Therapy versus No Opioid Replacement Therapy for Opioid Dependence., Cochrane Database Syst. Rev., 2009, p. CD002209 9 false true Reference 69493480 /api/reference/69493480 10. Abraham 2020: Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA., Neurotherapeutics, 17, p. 55, DOI: 10.1007/s13311-019-00814-4 10 10.1007/s13311-019-00814-4 false true Reference 69493481 /api/reference/69493481 11. Schuckit 2016: Treatment of Opioid-Use Disorders., N. Engl. J. Med., 375, p. 357, DOI: 10.1056/NEJMra1604339 11 10.1056/NEJMra1604339 false true Reference 69493482 /api/reference/69493482 12. Falconnier 2023: Functional Genomic Mechanisms of Opioid Action and Opioid Use Disorder: A Systematic Review of Animal Models and Human Studies., Mol. Psychiatry, 28, p. 4568, DOI: 10.1038/s41380-023-02238-1 12 10.1038/s41380-023-02238-1 false true Reference 69493483 /api/reference/69493483 13. David 1994: Differentiation of Intracranial Morphine Self-Administration Behavior among Five Brain Regions in Mice., Pharmacol. Biochem. Behav., 48, p. 625, DOI: 10.1016/0091-3057(94)90324-7 13 10.1016/0091-3057(94)90324-7 false true Reference 69493484 /api/reference/69493484 14. David 2000: Anatomical and Pharmacological Specificity of the Rewarding Effect Elicited by Microinjections of Morphine into the Nucleus Accumbens of Mice., Psychopharmacology, 150, p. 24, DOI: 10.1007/s002130000425 14 10.1007/s002130000425 false true Reference 69493485 /api/reference/69493485 15. Olmstead 1997: The Development of a Conditioned Place Preference to Morphine: Effects of Microinjections into Various CNS Sites., Behav. Neurosci., 111, p. 1324, DOI: 10.1037/0735-7044.111.6.1324 15 10.1037/0735-7044.111.6.1324 false true Reference 69493486 /api/reference/69493486 16. Phillips 1980: Reinforcing Effects of Morphine Microinjection into the Ventral Tegmental Area., Pharmacol. Biochem. Behav., 12, p. 965, DOI: 10.1016/0091-3057(80)90460-8 16 10.1016/0091-3057(80)90460-8 false true Reference 69493487 /api/reference/69493487 17. Volkow 2014: Medication-Assisted Therapies—Tackling the Opioid-Overdose Epidemic., N. Engl. J. Med., 370, p. 2063, DOI: 10.1056/NEJMp1402780 17 10.1056/NEJMp1402780 false true Reference 69493488 /api/reference/69493488 18. Cao 2023: Insights into the Mechanisms Underlying Opioid Use Disorder and Potential Treatment Strategies., Br. J. Pharmacol., 180, p. 862, DOI: 10.1111/bph.15592 18 10.1111/bph.15592 false true Reference 69493489 /api/reference/69493489 19. Dunn 2019: Non-Opioid Neurotransmitter Systems That Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence., J. Pharmacol. Exp. Ther., 371, p. 422, DOI: 10.1124/jpet.119.258004 19 10.1124/jpet.119.258004 false true Reference 69493490 /api/reference/69493490 20. Aguilar 2009: Memantine Blocks Sensitization to the Rewarding Effects of Morphine., Brain Res., 1288, p. 95, DOI: 10.1016/j.brainres.2009.06.100 20 10.1016/j.brainres.2009.06.100 false true Reference 69493491 /api/reference/69493491 21. Bespalov 1996: Intraaccumbens Administration of NMDA Receptor Antagonist (±)-CPP Prevents Locomotor Activation Conditioned by Morphine and Amphetamine in Rats., Pharmacol. Biochem. Behav., 55, p. 203, DOI: 10.1016/S0091-3057(96)00065-2 21 10.1016/S0091-3057(96)00065-2 false true Reference 69493492 /api/reference/69493492 22. Ma 2006: The Role of NR2B Containing NMDA Receptor in Place Preference Conditioned with Morphine and Natural Reinforcers in Rats., Exp. Neurol., 200, p. 343, DOI: 10.1016/j.expneurol.2006.02.117 22 10.1016/j.expneurol.2006.02.117 false true Reference 69493493 /api/reference/69493493 23. Ma 2007: NR2B-Containing NMDA Receptor Is Required for Morphine-but Not Stress-Induced Reinstatement., Exp. Neurol., 203, p. 309, DOI: 10.1016/j.expneurol.2006.08.014 23 10.1016/j.expneurol.2006.08.014 false true Reference 69493494 /api/reference/69493494 24. Jacobs 2005: Morphine Causes a Delayed Increase in Glutamate Receptor Functioning in the Nucleus Accumbens Core., Eur. J. Pharmacol., 511, p. 27, DOI: 10.1016/j.ejphar.2005.02.009 24 10.1016/j.ejphar.2005.02.009 false true Reference 69493495 /api/reference/69493495 25. Galambos, A.R., Papp, Z.T., Boldizsár, I., Zádor, F., Köles, L., Harsing, L.G., and Al-Khrasani, M. (2024). Glycine Transporter 1 Inhibitors: Predictions on Their Possible Mechanisms in the Development of Opioid Analgesic Tolerance. Biomedicines, 12., DOI: 10.3390/biomedicines12020421 25 10.3390/biomedicines12020421 false true Reference 69493496 /api/reference/69493496 26. Galambos, A.R., Essmat, N., Lakatos, P.P., Szücs, E., Boldizsár, I., Abbood, S.K., Karádi, D., Kirchlechner-Farkas, J.M., Király, K., and Benyhe, S. (2024). Glycine Transporter 1 Inhibitors Minimize the Analgesic Tolerance to Morphine. Int. J. Mol. Sci., 25., DOI: 10.3390/ijms252011136 26 10.3390/ijms252011136 false true Reference 69493497 /api/reference/69493497 27. Nestler 2005: Is There a Common Molecular Pathway for Addiction?., Nat. Neurosci., 8, p. 1445, DOI: 10.1038/nn1578 27 10.1038/nn1578 false true Reference 69493498 /api/reference/69493498 28. Listos, J., Łupina, M., Talarek, S., Mazur, A., Orzelska-Górka, J., and Kotlińska, J. (2019). The Mechanisms Involved in Morphine Addiction: An Overview. Int. J. Mol. Sci., 20., DOI: 10.3390/ijms20174302 28 10.3390/ijms20174302 false true Reference 69493499 /api/reference/69493499 29. Kaplan, G.B., and Thompson, B.L. (2023). Neuroplasticity of the Extended Amygdala in Opioid Withdrawal and Prolonged Opioid Abstinence. Front. Pharmacol., 14., DOI: 10.3389/fphar.2023.1253736 29 10.3389/fphar.2023.1253736 false true Reference 69493500 /api/reference/69493500 30. Baik 2020: Stress and the Dopaminergic Reward System., Exp. Mol. Med., 52, p. 1879, DOI: 10.1038/s12276-020-00532-4 30 10.1038/s12276-020-00532-4 false true Reference 69493501 /api/reference/69493501 31. Yoshida 1999: Fentanyl Increases Dopamine Release in Rat Nucleus Accumbens: Involvement of Mesolimbic MU- and Delta-2-Opioid Receptors., Neuroscience, 92, p. 1357, DOI: 10.1016/S0306-4522(99)00046-9 31 10.1016/S0306-4522(99)00046-9 false true Reference 69493502 /api/reference/69493502 32. Han 2025: Global, Regional, and National Epidemiology of Opioid Use Disorder Among Adolescents and Young Adults, 1990–2019., J. Adolesc. Health, 76, p. 905, DOI: 10.1016/j.jadohealth.2024.12.015 32 10.1016/j.jadohealth.2024.12.015 false true Reference 69493503 /api/reference/69493503 33. Wise 1995: Elevations of Nucleus Accumbens Dopamine and DOPAC Levels during Intravenous Heroin Self-administration., Synapse, 21, p. 140, DOI: 10.1002/syn.890210207 33 10.1002/syn.890210207 false true Reference 69493504 /api/reference/69493504 34. Gooding, S.W., Lewis, E., Chau, C., Sandhu, S., Glienke, J., and Whistler, J.L. (2024). Nucleus Accumbens Sub-Regions Experience Distinct Dopamine Release Responses Following Acute and Chronic Morphine Exposure. bioRxiv., DOI: 10.1101/2024.06.28.601282 34 10.1101/2024.06.28.601282 false true Reference 69493505 /api/reference/69493505 35. Mabrouk 2014: Rapid Dopamine Transmission within the Nucleus Accumbens: Dramatic Difference between Morphine and Oxycodone Delivery., Eur. J. Neurosci., 40, p. 3041, DOI: 10.1111/ejn.12709 35 10.1111/ejn.12709 false true Reference 69493506 /api/reference/69493506 36. Spanagel 1993: Long Lasting Changes in Morphine-induced Mesolimbic Dopamine Release after Chronic Morphine Exposure., Synapse, 14, p. 243, DOI: 10.1002/syn.890140307 36 10.1002/syn.890140307 false true Reference 69493507 /api/reference/69493507 37. Maisonneuve 2001: Biphasic Dose-Related Effects of Morphine on Dopamine Release., Drug Alcohol Depend., 65, p. 55, DOI: 10.1016/S0376-8716(01)00150-8 37 10.1016/S0376-8716(01)00150-8 false true Reference 69493508 /api/reference/69493508 38. Pieretti 1999: Orphanin FQ Reduces Morphine-Induced Dopamine Release in the Nucleus Accumbens: A Microdialysis Study in Rats., Neurosci. Lett., 272, p. 183, DOI: 10.1016/S0304-3940(99)00579-0 38 10.1016/S0304-3940(99)00579-0 false true Reference 69493509 /api/reference/69493509 39. Pothos 1991: Dopamine Microdialysis in the Nucleus Accumbens during Acute and Chronic Morphine, Naloxone-Precipitated Withdrawal and Clonidine Treatment., Brain Res., 566, p. 348, DOI: 10.1016/0006-8993(91)91724-F 39 10.1016/0006-8993(91)91724-F false true Reference 69493510 /api/reference/69493510 40. Acquas 1991: Profound Depression of Mesolimbic Dopamine Release after Morphine Withdrawal in Dependent Rats., Eur. J. Pharmacol., 193, p. 133, DOI: 10.1016/0014-2999(91)90214-B 40 10.1016/0014-2999(91)90214-B false true Reference 69493511 /api/reference/69493511 41. Samson 2022: Intermittent Access to Oxycodone Decreases Dopamine Uptake in the Nucleus Accumbens Core during Abstinence., Addict. Biol., 27, p. e13241, DOI: 10.1111/adb.13241 41 10.1111/adb.13241 false true Reference 69493512 /api/reference/69493512 42. Puskina 2020: Ghrelin Receptor Antagonism of Fentanyl-Induced Conditioned Place Preference, Intravenous Self-Administration, and Dopamine Release in the Nucleus Accumbens in Rats., Addict. Biol., 25, p. e12845, DOI: 10.1111/adb.12845 42 10.1111/adb.12845 false true Reference 69493513 /api/reference/69493513 43. Ferber, S.G., Weller, A., Yadid, G., and Friedman, A. (2021). Discovering the Lost Reward: Critical Locations for Endocannabinoid Modulation of the Cortico–Striatal Loop That Are Implicated in Major Depression. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms22041867 43 10.3390/ijms22041867 false true Reference 69493514 /api/reference/69493514 44. Gangarossa, G., Espallergues, J., d’Exaerde, A.d.K., El Mestikawy, S., Gerfen, C.R., Hervé, D., Girault, J.A., and Valjent, E. (2013). Distribution and Compartmental Organization of GABAergic Medium-Sized Spiny Neurons in the Mouse Nucleus Accumbens. Front. Neural Circuits, 7., DOI: 10.3389/fncir.2013.00022 44 10.3389/fncir.2013.00022 false true Reference 69493515 /api/reference/69493515 45. Chartoff, E.H., and Connery, H.S. (2014). It’s MORe Exciting than Mu: Crosstalk between Mu Opioid Receptors and Glutamatergic Transmission in the Mesolimbic Dopamine System. Front. Pharmacol., 5., DOI: 10.3389/fphar.2014.00116 45 10.3389/fphar.2014.00116 false true Reference 69493516 /api/reference/69493516 46. Hosseinzadeh Sahafi, O., Sardari, M., Alijanpour, S., and Rezayof, A. (2023). Shared Mechanisms of GABAergic and Opioidergic Transmission Regulate Corticolimbic Reward Systems and Cognitive Aspects of Motivational Behaviors. Brain Sci., 13., DOI: 10.3390/brainsci13050815 46 10.3390/brainsci13050815 false true Reference 69493517 /api/reference/69493517 47. Bonci 1997: Increased Probability of GABA Release during Withdrawal from Morphine., J. Neurosci., 17, p. 796, DOI: 10.1523/JNEUROSCI.17-02-00796.1997 47 10.1523/JNEUROSCI.17-02-00796.1997 false true Reference 69493518 /api/reference/69493518 48. Xi 2002: Gabaergic Mechanisms of Opiate Reinforcement., Alcohol., 37, p. 485, DOI: 10.1093/alcalc/37.5.485 48 10.1093/alcalc/37.5.485 false true Reference 69493519 /api/reference/69493519 49. Matsui 2011: Opioid-Sensitive GABA Inputs from Rostromedial Tegmental Nucleus Synapse onto Midbrain Dopamine Neurons., J. Neurosci., 31, p. 17729, DOI: 10.1523/JNEUROSCI.4570-11.2011 49 10.1523/JNEUROSCI.4570-11.2011 false true Reference 69493520 /api/reference/69493520 50. Moussawi 2020: Fentanyl Vapor Self-Administration Model in Mice to Study Opioid Addiction., Sci. Adv., 6, p. eabc0413, DOI: 10.1126/sciadv.abc0413 50 10.1126/sciadv.abc0413 false true Reference 69493521 /api/reference/69493521 51. Bajo, M., Madamba, S.G., Roberto, M., and Siggins, G.R. (2014). Acute Morphine Alters GABAergic Transmission in the Central Amygdala during Naloxone-Precipitated Morphine Withdrawal: Role of Cyclic AMP. Front. Integr. Neurosci., 8., DOI: 10.3389/fnint.2014.00045 51 10.3389/fnint.2014.00045 false true Reference 69493522 /api/reference/69493522 52. Xhakaza 2021: Alterations in Neurotransmitter Levels and Transcription Factor Expression Following Intranasal Buprenorphine Administration., Biomed. Pharmacother., 138, p. 111515, DOI: 10.1016/j.biopha.2021.111515 52 10.1016/j.biopha.2021.111515 false true Reference 69493523 /api/reference/69493523 53. Li 2020: Prefrontal GABA and Glutamate Levels Correlate with Impulsivity and Cognitive Function of Prescription Opioid Addicts: A 1H-Magnetic Resonance Spectroscopy Study., Psychiatry Clin. Neurosci., 74, p. 77, DOI: 10.1111/pcn.12940 53 10.1111/pcn.12940 false true Reference 69493524 /api/reference/69493524 54. Popova 2019: Synaptic Regulation by OPRM1 Variants in Reward Neurocircuitry., J. Neurosci., 39, p. 5685, DOI: 10.1523/JNEUROSCI.2317-18.2019 54 10.1523/JNEUROSCI.2317-18.2019 false true Reference 69493525 /api/reference/69493525 55. Kallupi 2020: Nociceptin Attenuates the Escalation of Oxycodone Self-Administration by Normalizing CeA-GABA Transmission in Highly Addicted Rats., Proc. Natl. Acad. Sci. USA, 117, p. 2140, DOI: 10.1073/pnas.1915143117 55 10.1073/pnas.1915143117 false true Reference 69493526 /api/reference/69493526 56. Hermenau 2023: A Retrospective Comparison of the Effectiveness of Buprenorphine Versus Baclofen for Acute Opioid Withdrawal., HCA Healthc. J. Med., 4, p. 11, DOI: 10.36518/2689-0216.1498 56 10.36518/2689-0216.1498 false true Reference 69493527 /api/reference/69493527 57. Vendruscolo 2023: Inhibition of Dorsal Raphe GABAergic Neurons Blocks Hyperalgesia during Heroin Withdrawal., Neuropsychopharmacology, 48, p. 1300, DOI: 10.1038/s41386-023-01620-5 57 10.1038/s41386-023-01620-5 false true Reference 69493528 /api/reference/69493528 58. von Gilsa, A., Steiner, J., Gos, A., Trübner, K., Mawrin, C., Kaliszan, M., Nickl-Jockschat, T., and Gos, T. (2025). Impairment of the GABAergic System in the Anterior Midcingulate Cortex of Heroin-Addicted Males. Eur. Arch. Psychiatry Clin. Neurosci., 1–8., DOI: 10.1007/s00406-025-01992-3 58 10.1007/s00406-025-01992-3 false true Reference 69493529 /api/reference/69493529 59. Gos 2025: Impairment of the GABAergic System in the Anterior Insular Cortex of Heroin-Addicted Males., Eur. Arch. Psychiatry Clin. Neurosci., 275, p. 219, DOI: 10.1007/s00406-024-01848-2 59 10.1007/s00406-024-01848-2 false true Reference 69493530 /api/reference/69493530 60. Pachenari 2025: Reduced GIRK Expression in Midbrain Dopamine Neurons during Prolonged Abstinence from Fentanyl Self-Administration., Psychopharmacology, 242, p. 1653, DOI: 10.1007/s00213-025-06747-5 60 10.1007/s00213-025-06747-5 false true Reference 69493531 /api/reference/69493531 61. Akuzawa 2023: Effect of ASP8062 on Morphine Self-Administration and Morphine-Induced Respiratory Suppression in Monkeys., J. Pharmacol. Sci., 151, p. 171, DOI: 10.1016/j.jphs.2023.02.003 61 10.1016/j.jphs.2023.02.003 false true Reference 69493532 /api/reference/69493532 62. Sun, K., Mu, Q., Chang, H., Zhang, C., Wang, Y., Rong, S., Liu, S., Zuo, D., He, Z., and Wan, D. (2020). Postretrieval Microinjection of Baclofen Into the Agranular Insular Cortex Inhibits Morphine-Induced CPP by Disrupting Reconsolidation. Front. Pharmacol., 11., DOI: 10.3389/fphar.2020.00743 62 10.3389/fphar.2020.00743 false true Reference 69493533 /api/reference/69493533 63. Li 2013: Effects of Inactivating the Agranular or Granular Insular Cortex on the Acquisition of the Morphine-Induced Conditioned Place Preference and Naloxone-Precipitated Conditioned Place Aversion in Rats., J. Psychopharmacol., 27, p. 837, DOI: 10.1177/0269881113492028 63 10.1177/0269881113492028 false true Reference 69493534 /api/reference/69493534 64. Defelipe 2013: New Insights into the Classification and Nomenclature of Cortical GABAergic Interneurons., Nat. Rev. Neurosci., 14, p. 202, DOI: 10.1038/nrn3444 64 10.1038/nrn3444 false true Reference 69493535 /api/reference/69493535 65. He 2021: Convergent, Functionally Independent Signaling by Mu and Delta Opioid Receptors in Hippocampal Parvalbumin Interneurons., eLife, 10, p. e69746, DOI: 10.7554/eLife.69746 65 10.7554/eLife.69746 false true Reference 69493536 /api/reference/69493536 66. Shao 2020: Mu Opioid Receptors Inhibit GABA Release from Parvalbumin Interneuron Terminals onto CA1 Pyramidal Cells., Biochem. Biophys. Res. Commun., 522, p. 1059, DOI: 10.1016/j.bbrc.2019.12.013 66 10.1016/j.bbrc.2019.12.013 false true Reference 69493537 /api/reference/69493537 67. Caccavano 2025: Divergent Opioid-Mediated Suppression of Inhibition between Hippocampus and Neocortex across Species and Development., Neuron, 113, p. 1805, DOI: 10.1016/j.neuron.2025.03.005 67 10.1016/j.neuron.2025.03.005 false true Reference 69493538 /api/reference/69493538 68. Bouarab, C., Thompson, B., and Polter, A.M. (2019). VTA GABA Neurons at the Interface of Stress and Reward. Front. Neural Circuits, 13., DOI: 10.3389/fncir.2019.00078 68 10.3389/fncir.2019.00078 false true Reference 69493539 /api/reference/69493539 69. Reeves, K.C., Shah, N., Muñoz, B., and Atwood, B.K. (2022). Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain. Front. Mol. Neurosci., 15., DOI: 10.3389/fnmol.2022.919773 69 10.3389/fnmol.2022.919773 false true Reference 69493540 /api/reference/69493540 70. Drake 2002: Mu Opioid Receptors Are in Discrete Hippocampal Interneuron Subpopulations., Hippocampus, 12, p. 119, DOI: 10.1002/hipo.1107 70 10.1002/hipo.1107 false true Reference 69493541 /api/reference/69493541 71. Cattaneo, S., Zaghi, M., Maddalena, R., Bedogni, F., Sessa, A., and Taverna, S. (2019). Somatostatin-Expressing Interneurons Co-Release GABA and Glutamate onto Different Postsynaptic Targets in the Striatum. bioRxiv., DOI: 10.1101/566984 71 10.1101/566984 false true Reference 69493542 /api/reference/69493542 72. Kecskés, A., Pohóczky, K., Kecskés, M., Varga, Z.V., Kormos, V., Szőke, É., Henn-Mike, N., Fehér, M., Kun, J., and Gyenesei, A. (2020). Characterization of Neurons Expressing the Novel Analgesic Drug Target Somatostatin Receptor 4 in Mouse and Human Brains. Int. J. Mol. Sci., 21., DOI: 10.3390/ijms21207788 72 10.3390/ijms21207788 false true Reference 69493543 /api/reference/69493543 73. Turi 2019: Vasoactive Intestinal Polypeptide-Expressing Interneurons in the Hippocampus Support Goal-Oriented Spatial Learning., Neuron, 101, p. 1150, DOI: 10.1016/j.neuron.2019.01.009 73 10.1016/j.neuron.2019.01.009 false true Reference 69493544 /api/reference/69493544 74. Leroy 2022: Enkephalin Release from VIP Interneurons in the Hippocampal CA2/3a Region Mediates Heterosynaptic Plasticity and Social Memory., Mol. Psychiatry, 27, p. 2879, DOI: 10.1038/s41380-021-01124-y 74 10.1038/s41380-021-01124-y false true Reference 69493545 /api/reference/69493545 75. 1998: Enkephalin-Containing Interneurons Are Specialized to Innervate Other Interneurons in the Hippocampal CA1 Region of the Rat and Guinea-Pig., Eur. J. Neurosci., 10, p. 1784, DOI: 10.1046/j.1460-9568.1998.00190.x 75 10.1046/j.1460-9568.1998.00190.x false true Reference 69493546 /api/reference/69493546 76. Berríos-Cárcamo, P., Quezada, M., Santapau, D., Morales, P., Olivares, B., Ponce, C., Ávila, A., De Gregorio, C., Ezquer, M., and Quintanilla, M.E. (2022). A Novel Morphine Drinking Model of Opioid Dependence in Rats. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23073874 76 10.3390/ijms23073874 false true Reference 69493547 /api/reference/69493547 77. Neubrandt, M., Lenkey, N., and Vervaeke, K. (2025). VIP Interneurons Control Hippocampal Place Cell Remapping through Transient Disinhibition in Novel Environments. bioRxiv., DOI: 10.1101/2025.02.01.636072 77 10.1101/2025.02.01.636072 false true Reference 69493548 /api/reference/69493548 78. Merrill 2015: Ventral Tegmental Area Dopamine and GABA Neurons: Physiological Properties and Expression of MRNA for Endocannabinoid Biosynthetic Elements., Sci. Rep., 5, p. 16176, DOI: 10.1038/srep16176 78 10.1038/srep16176 false true Reference 69493549 /api/reference/69493549 79. Viena 2021: Calretinin and Calbindin Architecture of the Midline Thalamus Associated with Prefrontal–Hippocampal Circuitry., Hippocampus, 31, p. 770, DOI: 10.1002/hipo.23271 79 10.1002/hipo.23271 false true Reference 69493550 /api/reference/69493550 80. Oriol 2025: Ventral Tegmental Area Interneurons Revisited: GABA and Glutamate Projection Neurons Make Local Synapses., eLife, 13, p. 100085, DOI: 10.7554/eLife.100085.3 80 10.7554/eLife.100085.3 false true Reference 69493551 /api/reference/69493551 81. Matsui 2014: Separate GABA Afferents to Dopamine Neurons Mediate Acute Action of Opioids, Development of Tolerance, and Expression of Withdrawal., Neuron, 82, p. 1346, DOI: 10.1016/j.neuron.2014.04.030 81 10.1016/j.neuron.2014.04.030 false true Reference 69493552 /api/reference/69493552 82. Castro 2019: A Motivational and Neuropeptidergic Hub: Anatomical and Functional Diversity within the Nucleus Accumbens Shell., Neuron, 102, p. 529, DOI: 10.1016/j.neuron.2019.03.003 82 10.1016/j.neuron.2019.03.003 false true Reference 69493553 /api/reference/69493553 83. Fields 2015: Understanding Opioid Reward., Trends Neurosci., 38, p. 217, DOI: 10.1016/j.tins.2015.01.002 83 10.1016/j.tins.2015.01.002 false true Reference 69493554 /api/reference/69493554 84. Kuwana 2006: Electrophysiological and Morphological Characteristics of GABAergic Respiratory Neurons in the Mouse Pre-Bötzinger Complex., Eur. J. Neurosci., 23, p. 667, DOI: 10.1111/j.1460-9568.2006.04591.x 84 10.1111/j.1460-9568.2006.04591.x false true Reference 69493555 /api/reference/69493555 85. Yajima 1999: Ambiguous Respiratory Neurons Are Modulated by GABA(A) Receptor-Mediated Inhibition., Neuroscience, 90, p. 249, DOI: 10.1016/S0306-4522(98)00419-9 85 10.1016/S0306-4522(98)00419-9 false true Reference 69493556 /api/reference/69493556 86. Baertsch 2018: The Interdependence of Excitation and Inhibition for the Control of Dynamic Breathing Rhythms., Nat. Commun., 9, p. 843, DOI: 10.1038/s41467-018-03223-x 86 10.1038/s41467-018-03223-x false true Reference 69493557 /api/reference/69493557 87. Vaughan 1997: How Opioids Inhibit GABA-Mediated Neurotransmission., Nature, 390, p. 611, DOI: 10.1038/37610 87 10.1038/37610 false true Reference 69493558 /api/reference/69493558 88. Bobeck 2009: Drug Dependent Sex-Differences in Periaqueducatal Gray Mediated Antinociception in the Rat., Pain, 147, p. 210, DOI: 10.1016/j.pain.2009.09.008 88 10.1016/j.pain.2009.09.008 false true Reference 69493559 /api/reference/69493559 89. Hughes 2020: Central Nervous System Targets: Inhibitory Interneurons in the Spinal Cord., Neurotherapeutics, 17, p. 874, DOI: 10.1007/s13311-020-00936-0 89 10.1007/s13311-020-00936-0 false true Reference 69493560 /api/reference/69493560 90. Davis 2019: Expression of Calretinin Among Different Neurochemical Classes of Interneuron in the Superficial Dorsal Horn of the Mouse Spinal Cord., Neuroscience, 398, p. 171, DOI: 10.1016/j.neuroscience.2018.12.009 90 10.1016/j.neuroscience.2018.12.009 false true Reference 69493561 /api/reference/69493561 91. Fatima 2019: Spinal Somatostatin-Positive Interneurons Transmit Chemical Itch., Pain, 160, p. 1166, DOI: 10.1097/j.pain.0000000000001499 91 10.1097/j.pain.0000000000001499 false true Reference 69493562 /api/reference/69493562 92. Glerup 2014: Immunofluorescent Visualization of Mouse Interneuron Subtypes., F1000Research, 3, p. 242 92 false true Reference 69493563 /api/reference/69493563 93. Pasternak 2013: Mu Opioids and Their Receptors: Evolution of a Concept., Pharmacol. Rev., 65, p. 1257, DOI: 10.1124/pr.112.007138 93 10.1124/pr.112.007138 false true Reference 69493564 /api/reference/69493564 94. Lu 2018: Truncated μ-Opioid Receptors with 6 Transmembrane Domains Are Essential for Opioid Analgesia., Anesth. Analg., 126, p. 1050, DOI: 10.1213/ANE.0000000000002538 94 10.1213/ANE.0000000000002538 false true Reference 69493565 /api/reference/69493565 95. Zhang 2012: Signaling Cascades for δ-Opioid Receptor-Mediated Inhibition of Gaba Synaptic Transmission and Behavioral Antinociception., Mol. Pharmacol., 81, p. 375, DOI: 10.1124/mol.111.076307 95 10.1124/mol.111.076307 false true Reference 69493566 /api/reference/69493566 96. Zhang 2010: Synaptic Mechanism for Functional Synergism between δ- And μ-Opioid Receptors., J. Neurosci., 30, p. 4735, DOI: 10.1523/JNEUROSCI.5968-09.2010 96 10.1523/JNEUROSCI.5968-09.2010 false true Reference 69493567 /api/reference/69493567 97. Nutt 2008: Addiction: The Clinical Interface., Br. J. Pharmacol., 154, p. 397, DOI: 10.1038/bjp.2008.101 97 10.1038/bjp.2008.101 false true Reference 69493568 /api/reference/69493568 98. Jones, G.C., Small, C.A., Otteson, D.Z., Hafen, C.W., Breinholt, J.T., Flora, P.D., Burris, M.D., Sant, D.W., Ruchti, T.R., and Yorgason, J.T. (2023). Whole-Body Vibration Prevents Neuronal, Neurochemical, and Behavioral Effects of Morphine Withdrawal in a Rat Model. Int. J. Mol. Sci., 24., DOI: 10.3390/ijms241814147 98 10.3390/ijms241814147 false true Reference 69493569 /api/reference/69493569 99. Tang 2023: Association between Methylation in the Promoter Region of the GAD2 Gene and Opioid Use Disorder., Brain Res., 1812, p. 148407, DOI: 10.1016/j.brainres.2023.148407 99 10.1016/j.brainres.2023.148407 false true Reference 69493570 /api/reference/69493570 100. Hasbi 2020: Dopamine D1-D2 Receptor Heteromer Expression in Key Brain Regions of Rat and Higher Species: Upregulation in Rat Striatum after Cocaine Administration., Neurobiol. Dis., 143, p. 105017, DOI: 10.1016/j.nbd.2020.105017 100 10.1016/j.nbd.2020.105017 false true Reference 69493571 /api/reference/69493571 101. Bosch 2008: Opposing Patterns of Signaling Activation in Dopamine D1 and D2 Receptor-Expressing Striatal Neurons in Response to Cocaine and Haloperidol., J. Neurosci., 28, p. 5671, DOI: 10.1523/JNEUROSCI.1039-08.2008 101 10.1523/JNEUROSCI.1039-08.2008 false true Reference 69493572 /api/reference/69493572 102. Berendse 1992: Topographical Organization and Relationship with Ventral Striatal Compartments of Prefrontal Corticostriatal Projections in the Rat., J. Comp. Neurol., 316, p. 314, DOI: 10.1002/cne.903160305 102 10.1002/cne.903160305 false true Reference 69493573 /api/reference/69493573 103. Pignatelli 2019: Valence Coding in Amygdala Circuits., Curr. Opin. Behav. Sci., 26, p. 97, DOI: 10.1016/j.cobeha.2018.10.010 103 10.1016/j.cobeha.2018.10.010 false true Reference 69493574 /api/reference/69493574 104. Zhu 2016: A Thalamic Input to the Nucleus Accumbens Mediates Opiate Dependence., Nature, 530, p. 219, DOI: 10.1038/nature16954 104 10.1038/nature16954 false true Reference 69493575 /api/reference/69493575 105. Qi 2016: VTA Glutamatergic Inputs to Nucleus Accumbens Drive Aversion by Acting on GABAergic Interneurons., Nat. Neurosci., 19, p. 725, DOI: 10.1038/nn.4281 105 10.1038/nn.4281 false true Reference 69493576 /api/reference/69493576 106. Vachez 2021: Ventral Arkypallidal Neurons Inhibit Accumbal Firing to Promote Reward Consumption., Nat. Neurosci., 24, p. 379, DOI: 10.1038/s41593-020-00772-7 106 10.1038/s41593-020-00772-7 false true Reference 69493577 /api/reference/69493577 107. Beier 2015: Circuit Architecture of VTA Dopamine Neurons Revealed by Systematic Input-Output Mapping., Cell, 162, p. 622, DOI: 10.1016/j.cell.2015.07.015 107 10.1016/j.cell.2015.07.015 false true Reference 69493578 /api/reference/69493578 108. Scofield 2016: The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis., Pharmacol. Rev., 68, p. 816, DOI: 10.1124/pr.116.012484 108 10.1124/pr.116.012484 false true Reference 69493579 /api/reference/69493579 109. Brown 2012: Ventral Tegmental Area GABA Projections Pause Accumbal Cholinergic Interneurons to Enhance Associative Learning., Nature, 492, p. 452, DOI: 10.1038/nature11657 109 10.1038/nature11657 false true Reference 69493580 /api/reference/69493580 110. Wu 2025: Presynaptic Mu Opioid Receptors Suppress the Functional Connectivity of Ventral Tegmental Area Dopaminergic Neurons with Aversion-Related Brain Regions., J. Neurosci., 45, p. e1194242025, DOI: 10.1523/JNEUROSCI.1194-24.2025 110 10.1523/JNEUROSCI.1194-24.2025 false true Reference 69493581 /api/reference/69493581 111. Mamaligas 2016: Nicotinic and Opioid Receptor Regulation of Striatal Dopamine D2-Receptor Mediated Transmission., Sci. Rep., 6, p. 37834, DOI: 10.1038/srep37834 111 10.1038/srep37834 false true Reference 69493582 /api/reference/69493582 112. Reeves 2025: Excitatory Synaptic Transmission Is Differentially Modulated by Opioid Receptors along the Claustro-Cingulate Pathway., eNeuro, 12, p. 1, DOI: 10.1523/ENEURO.0219-25.2025 112 10.1523/ENEURO.0219-25.2025 false true Reference 69493583 /api/reference/69493583 113. McGovern 2023: Ventral Tegmental Area Glutamate Neurons Establish a Mu-Opioid Receptor Gated Circuit to Mesolimbic Dopamine Neurons and Regulate Opioid-Seeking Behavior., Neuropsychopharmacology, 48, p. 1889, DOI: 10.1038/s41386-023-01637-w 113 10.1038/s41386-023-01637-w false true Reference 69493584 /api/reference/69493584 114. Lupica 2023: Control of Dopamine Communication by Opioids: Glutamate Enters the Discussion., Neuropsychopharmacology, 48, p. 1833, DOI: 10.1038/s41386-023-01683-4 114 10.1038/s41386-023-01683-4 false true Reference 69493585 /api/reference/69493585 115. Brown, M.T.C., Bellone, C., Mameli, M., Labouèbe, G., Bocklisch, C., Balland, B., Dahan, L., Luján, R., Deisseroth, K., and LüScher, C. (2010). Drug-Driven AMPA Receptor Redistribution Mimicked by Selective Dopamine Neuron Stimulation. PLoS ONE, 5., DOI: 10.1371/journal.pone.0015870 115 10.1371/journal.pone.0015870 false true Reference 69493586 /api/reference/69493586 116. Heinsbroek 2021: Glutamatergic Systems and Memory Mechanisms Underlying Opioid Addiction., Cold Spring Harb. Perspect. Med., 11, p. a039602, DOI: 10.1101/cshperspect.a039602 116 10.1101/cshperspect.a039602 false true Reference 69493587 /api/reference/69493587 117. Salisbury, A.J., Blackwood, C.A., and Cadet, J.L. (2021). Prolonged Withdrawal From Escalated Oxycodone Is Associated With Increased Expression of Glutamate Receptors in the Rat Hippocampus. Front. Neurosci., 14., DOI: 10.3389/fnins.2020.617973 117 10.3389/fnins.2020.617973 false true Reference 69493588 /api/reference/69493588 118. Lin, H., Olaniran, A., Luo, X., Strauch, J., Burke, M.A.M., Matheson, C.L., and Li, X. (2024). Orbitofrontal Cortex to Dorsal Striatum Circuit Is Critical for Incubation of Oxycodone Craving after Forced Abstinence. Addict. Biol., 29., DOI: 10.1111/adb.13440 118 10.1111/adb.13440 false true Reference 69493589 /api/reference/69493589 119. Chen 2024: Glutamatergic Neurons in Ventral Pallidum Modulate Heroin Addiction via Epithalamic Innervation in Rats., Acta Pharmacol. Sin., 45, p. 945, DOI: 10.1038/s41401-024-01229-4 119 10.1038/s41401-024-01229-4 false true Reference 69493590 /api/reference/69493590 120. Khatri 2024: Oxycodone Withdrawal Is Associated with Increased Cocaine Self-Administration and Aberrant Accumbens Glutamate Plasticity in Rats., Neuropharmacology, 242, p. 109773, DOI: 10.1016/j.neuropharm.2023.109773 120 10.1016/j.neuropharm.2023.109773 false true Reference 69493591 /api/reference/69493591 121. Dolgetta 2022: Sex and Chronic Stress Alter the Distribution of Glutamate Receptors within Rat Hippocampal CA3 Pyramidal Cells Following Oxycodone Conditioned Place Preference., Neurobiol. Stress, 17, p. 100431, DOI: 10.1016/j.ynstr.2022.100431 121 10.1016/j.ynstr.2022.100431 false true Reference 69493592 /api/reference/69493592 122. Xi 2002: Blockade of Ionotropic Glutamatergic Transmission in the Ventral Tegmental Area Reduces Heroin Reinforcement in Rat., Psychopharmacology, 164, p. 144, DOI: 10.1007/s00213-002-1190-3 122 10.1007/s00213-002-1190-3 false true Reference 69493593 /api/reference/69493593 123. Yang, Y., Bai, J., Sun, J.Y., Ye, T., Zhang, L., Wu, F.Y., Nan, J., and Lan, Y. (2022). Mechanisms Underlying Mu Opioid Receptor Effects on Parallel Fiber-Purkinje Cell Synaptic Transmission in Mouse Cerebellar Cortex. Front. Synaptic Neurosci., 14., DOI: 10.3389/fnsyn.2022.862704 123 10.3389/fnsyn.2022.862704 false true Reference 69493594 /api/reference/69493594 124. 2012: Direct Association of Mu-Opioid and NMDA Glutamate Receptors Supports Their Cross-Regulation: Molecular Implications for Opioid Tolerance., Curr. Drug Abus. Rev., 5, p. 199, DOI: 10.2174/1874473711205030199 124 10.2174/1874473711205030199 false true Reference 69493595 /api/reference/69493595 125. Berhow 1996: Regulation of ERK (Extracellular Signal Regulated Kinase), Part of the Neurotrophin Signal Transduction Cascade, in the Rat Mesolimbic Dopamine System by Chronic Exposure to Morphine or Cocaine., J. Neurosci., 16, p. 4707, DOI: 10.1523/JNEUROSCI.16-15-04707.1996 125 10.1523/JNEUROSCI.16-15-04707.1996 false true Reference 69493596 /api/reference/69493596 126. Ivanov 2006: Opposing Role of Synaptic and Extrasynaptic NMDA Receptors in Regulation of the Extracellular Signal-Regulated Kinases (ERK) Activity in Cultured Rat Hippocampal Neurons., J. Physiol., 572, p. 789, DOI: 10.1113/jphysiol.2006.105510 126 10.1113/jphysiol.2006.105510 false true Reference 69493597 /api/reference/69493597 127. Sun, W.L., Quizon, P.M., and Zhu, J. (2016). Molecular Mechanism: ERK Signaling, Drug Addiction, and Behavioral Effects. Progress in Molecular Biology and Translational Science, Elsevier., DOI: 10.1016/bs.pmbts.2015.10.017 127 10.1016/bs.pmbts.2015.10.017 false true Reference 69493598 /api/reference/69493598 128. Shen 2011: Heroin Relapse Requires Long-Term Potentiation-like Plasticity Mediated by NMDA2b-Containing Receptors., Proc. Natl. Acad. Sci. USA, 108, p. 19407, DOI: 10.1073/pnas.1112052108 128 10.1073/pnas.1112052108 false true Reference 69493599 /api/reference/69493599 129. Liu 2014: Dopamine D3 Receptor-Regulated NR2B Subunits of N-Methyl-d-Aspartate Receptors in the Nucleus Accumbens Involves in Morphine-Induced Locomotor Activity., CNS Neurosci. Ther., 20, p. 823, DOI: 10.1111/cns.12276 129 10.1111/cns.12276 false true Reference 69493600 /api/reference/69493600 130. Kao 2011: NR2B Subunit of NMDA Receptor at Nucleus Accumbens Is Involved in Morphine Rewarding Effect by SiRNA Study., Drug Alcohol. Depend., 118, p. 366, DOI: 10.1016/j.drugalcdep.2011.04.019 130 10.1016/j.drugalcdep.2011.04.019 false true Reference 69493601 /api/reference/69493601 131. Anderson 2015: Phosphorylation of the N-Methyl-D-Aspartate Receptor Is Increased in the Nucleus Accumbens during Both Acute and Extended Morphine Withdrawal., J. Pharmacol. Exp. Ther., 355, p. 496, DOI: 10.1124/jpet.115.227629 131 10.1124/jpet.115.227629 false true Reference 69493602 /api/reference/69493602 132. Ellis 2025: Machine Learning Analysis of the Orbitofrontal Cortex Transcriptome of Human Opioid Users Identifies Shisa7 as a Translational Target Relevant for Heroin Seeking Leveraging a Male Rat Model., Biol. Psychiatry, 98, p. 23, DOI: 10.1016/j.biopsych.2024.12.007 132 10.1016/j.biopsych.2024.12.007 false true Reference 69493603 /api/reference/69493603 133. Castellano 2022: Shisa7-Dependent Regulation of GABAA Receptor Single-Channel Gating Kinetics., J. Neurosci., 42, p. 8758, DOI: 10.1523/JNEUROSCI.0510-22.2022 133 10.1523/JNEUROSCI.0510-22.2022 false true Reference 69493604 /api/reference/69493604 134. Han 2019: Shisa7 Is a GABAAreceptor Auxiliary Subunit Controlling Benzodiazepine Actions., Science, 366, p. 246, DOI: 10.1126/science.aax5719 134 10.1126/science.aax5719 false true Reference 69493605 /api/reference/69493605 135. Xue 2022: Molecular Rhythm Alterations in Prefrontal Cortex and Nucleus Accumbens Associated with Opioid Use Disorder., Transl. Psychiatry, 12, p. 123, DOI: 10.1038/s41398-022-01894-1 135 10.1038/s41398-022-01894-1 false true Reference 69493606 /api/reference/69493606 136. Thompson 2020: Opioid-Induced Structural and Functional Plasticity of Medium-Spiny Neurons in the Nucleus Accumbens., Neurosci. Biobehav. Rev., 120, p. 417, DOI: 10.1016/j.neubiorev.2020.10.015 136 10.1016/j.neubiorev.2020.10.015 false true Reference 69493607 /api/reference/69493607 137. Spiga 2005: Morphine Withdrawal-Induced Morphological Changes in the Nucleus Accumbens., Eur. J. Neurosci., 22, p. 2332, DOI: 10.1111/j.1460-9568.2005.04416.x 137 10.1111/j.1460-9568.2005.04416.x false true Reference 69493608 /api/reference/69493608 138. Diana 2006: Persistent and Reversible Morphine Withdrawal-Induced Morphological Changes in the Nucleus Accumbens., Ann. N. Y. Acad. Sci., 1074, p. 446, DOI: 10.1196/annals.1369.045 138 10.1196/annals.1369.045 false true Reference 69493609 /api/reference/69493609 139. Kobrin 2014: Extinction of Opiate Reward Reduces Dendritic Arborization and C-Fos Expression in the Nucleus Accumbens Core., Behav. Brain Res., 263, p. 51, DOI: 10.1016/j.bbr.2013.12.041 139 10.1016/j.bbr.2013.12.041 false true Reference 69493610 /api/reference/69493610 140. Heng 2008: Repeated Morphine Exposure Decreased the Nucleus Accumbens Excitability during Short-Term Withdrawal., Synapse, 62, p. 775, DOI: 10.1002/syn.20551 140 10.1002/syn.20551 false true Reference 69493611 /api/reference/69493611 141. Wu 2012: Potentiation of Synaptic Strength and Intrinsic Excitability in the Nucleus Accumbens after 10 Days of Morphine Withdrawal., J. Neurosci. Res., 90, p. 1270, DOI: 10.1002/jnr.23025 141 10.1002/jnr.23025 false true Reference 69493612 /api/reference/69493612 142. Wu 2013: Effects of Morphine Withdrawal on the Membrane Properties of Medium Spiny Neurons in the Nucleus Accumbens Shell., Brain Res. Bull., 90, p. 92, DOI: 10.1016/j.brainresbull.2012.09.015 142 10.1016/j.brainresbull.2012.09.015 false true Reference 69493613 /api/reference/69493613 143. Fox 2022: Adaptations in Nucleus Accumbens Neuron Subtypes Mediate Negative Affective Behaviors in Fentanyl Abstinence., Biol. Psychiatry, 93, p. 489, DOI: 10.1016/j.biopsych.2022.08.023 143 10.1016/j.biopsych.2022.08.023 false true Reference 69493614 /api/reference/69493614 144. Georges 2000: Mapping of C-Fos Gene Expression in the Brain during Morphine Dependence and Precipitated Withdrawal, and Phenotypic Identification of the Striatal Neurons Involved., Eur. J. Neurosci., 12, p. 4475, DOI: 10.1046/j.0953-816X.2000.01334.x 144 10.1046/j.0953-816X.2000.01334.x false true Reference 69493615 /api/reference/69493615 145. Enoksson 2012: Nucleus Accumbens D2- and D1-Receptor Expressing Medium Spiny Neurons Are Selectively Activated by Morphine Withdrawal and Acute Morphine, Respectively., Neuropharmacology, 62, p. 2463, DOI: 10.1016/j.neuropharm.2012.02.020 145 10.1016/j.neuropharm.2012.02.020 false true Reference 69493616 /api/reference/69493616 146. Matamales, M., Bertran-Gonzalez, J., Salomon, L., Degos, B., Deniau, J.M., Valjent, E., Hervé, D., and Girault, J.A. (2009). Striatal Medium-Sized Spiny Neurons: Identification by Nuclear Staining and Study of Neuronal Subpopulations in BAC Transgenic Mice. PLoS ONE, 4., DOI: 10.1371/journal.pone.0004770 146 10.1371/journal.pone.0004770 false true Reference 69493617 /api/reference/69493617 147. Hearing 2016: Reversal of Morphine-Induced Cell-Type-Specific Synaptic Plasticity in the Nucleus Accumbens Shell Blocks Reinstatement., Proc. Natl. Acad. Sci. USA, 113, p. 757, DOI: 10.1073/pnas.1519248113 147 10.1073/pnas.1519248113 false true Reference 69493618 /api/reference/69493618 148. Madayag 2019: Cell-Type and Region-Specific Nucleus Accumbens AMPAR Plasticity Associated with Morphine Reward, Reinstatement, and Spontaneous Withdrawal., Brain Struct. Funct., 224, p. 2311, DOI: 10.1007/s00429-019-01903-y 148 10.1007/s00429-019-01903-y false true Reference 69493619 /api/reference/69493619 149. Shen, M.R., Campbell, D.E., Kopczynski, A., Maddams, S., Rosenblum, N., Nigam, K., and Suzuki, J. (2025). Ketamine in Treating Opioid Use Disorder and Opioid Withdrawal: A Scoping Review. Front. Psychiatry, 16., DOI: 10.3389/fpsyt.2025.1552084 149 10.3389/fpsyt.2025.1552084 false true Reference 69493620 /api/reference/69493620 150. Michael 2025: (2R,6R)-Hydroxynorketamine Prevents Opioid Abstinence-Related Negative Affect and Stress-Induced Reinstatement in Mice., Br. J. Pharmacol., 182, p. 3428, DOI: 10.1111/bph.70018 150 10.1111/bph.70018 false true Reference 69493621 /api/reference/69493621 151. Montemitro 2021: Mechanistic Insights into the Efficacy of Memantine in Treating Certain Drug Addictions., Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 111, p. 110409, DOI: 10.1016/j.pnpbp.2021.110409 151 10.1016/j.pnpbp.2021.110409 false true Reference 69493622 /api/reference/69493622 152. D’Souza, M.S. (2015). Glutamatergic Transmission in Drug Reward: Implications for Drug Addiction. Front. Neurosci., 9., DOI: 10.3389/fnins.2015.00404 152 10.3389/fnins.2015.00404 false true Reference 69493623 /api/reference/69493623 153. Nazari 2024: The Effect of Morphine Administration on GluN3B NMDA Receptor Subunit MRNA Expression in Rat Brain., Acta Neurobiol. Exp., 84, p. 89, DOI: 10.55782/ane-2024-2545 153 10.55782/ane-2024-2545 false true Reference 69493624 /api/reference/69493624 154. Galaj 2023: The Impact of Heroin Self-Administration and Environmental Enrichment on Ventral Tegmental CRF1 Receptor Expression., Int. J. Neuropsychopharmacol., 26, p. 828, DOI: 10.1093/ijnp/pyad060 154 10.1093/ijnp/pyad060 false true Reference 69493625 /api/reference/69493625 155. Hu 2018: AMPA Receptor Positive Allosteric Modulators Attenuate Morphine Tolerance and Dependence., Neuropharmacology, 137, p. 50, DOI: 10.1016/j.neuropharm.2018.04.020 155 10.1016/j.neuropharm.2018.04.020 false true Reference 69493626 /api/reference/69493626 156. Olianas 2012: Potentiation of Dopamine D1-like Receptor Signaling by Concomitant Activation of δ- And μ-Opioid Receptors in Mouse Medial Prefrontal Cortex., Neurochem. Int., 61, p. 1404, DOI: 10.1016/j.neuint.2012.10.005 156 10.1016/j.neuint.2012.10.005 false true Reference 69493627 /api/reference/69493627 157. Beckerman 2011: Ultrastructural Relationship between the AMPA-GluR2 Receptor Subunit and the Mu-Opioid Receptor in the Mouse Central Nucleus of the Amygdala., Exp. Neurol., 227, p. 149, DOI: 10.1016/j.expneurol.2010.10.010 157 10.1016/j.expneurol.2010.10.010 false true Reference 69493628 /api/reference/69493628 158. Chen 2011: Low Doses of Dextromethorphan Attenuate Morphine-Induced Rewarding via the Sigma-1 Receptor at Ventral Tegmental Area in Rats., Drug Alcohol. Depend., 117, p. 164, DOI: 10.1016/j.drugalcdep.2011.01.013 158 10.1016/j.drugalcdep.2011.01.013 false true Reference 69493629 /api/reference/69493629 159. Chittajallu, R., Vlachos, A., Yuan, X., Hunt, S., Abebe, D., London, E., Pelkey, K.A., and McBain, C.J. (2025). Complex Opioid Driven Modulation of Glutamatergic and Cholinergic Neurotransmission in a GABAergic Brain Nucleus Associated with Emotion, Reward and Addiction. bioRxiv., DOI: 10.7554/eLife.106062.1 159 10.7554/eLife.106062.1 false true Reference 69493630 /api/reference/69493630 160. Xie 2025: Association Between the (GT)26 Allele in the GRIN2A Promoter and Opioid Use Disorder., Psychiatry Investig., 22, p. 730, DOI: 10.30773/pi.2025.0090 160 10.30773/pi.2025.0090 false true Reference 69493631 /api/reference/69493631 161. Raiteri, L. (2024). Interactions Involving Glycine and Other Amino Acid Neurotransmitters: Focus on Transporter-Mediated Regulation of Release and Glycine–Glutamate Crosstalk. Biomedicines, 12., DOI: 10.3390/biomedicines12071518 161 10.3390/biomedicines12071518 false true Reference 69493632 /api/reference/69493632 162. Johnson 1987: Glycine Potentiates the NMDA Response in Cultured Mouse Brain Neurons., Nature, 325, p. 529, DOI: 10.1038/325529a0 162 10.1038/325529a0 false true Reference 69493633 /api/reference/69493633 163. Otsu 2019: Control of Aversion by Glycine-Gated GluN1/GluN3A NMDA Receptors in the Adult Medial Habenula., Science, 366, p. 250, DOI: 10.1126/science.aax1522 163 10.1126/science.aax1522 false true Reference 69493634 /api/reference/69493634 164. Laboute 2023: Orphan Receptor GPR158 Serves as a Metabotropic Glycine Receptor: MGlyR., Science, 379, p. 1352, DOI: 10.1126/science.add7150 164 10.1126/science.add7150 false true Reference 69493635 /api/reference/69493635 165. Li 2006: Opposite Effects of MK-801 on the Expression of Food and Morphine-Induced Conditioned Place Preference in Rats., J. Psychopharmacol., 20, p. 40, DOI: 10.1177/0269881105057250 165 10.1177/0269881105057250 false true Reference 69493636 /api/reference/69493636 166. Aguilar 2004: Effects of NMDA Receptor Antagonists (MK-801 and Memantine) on the Acquisition of Morphine-Induced Conditioned Place Preference in Mice., Prog. Neuropsychopharmacol. Biol. Psychiatry, 28, p. 1035, DOI: 10.1016/j.pnpbp.2004.05.038 166 10.1016/j.pnpbp.2004.05.038 false true Reference 69493637 /api/reference/69493637 167. Papp 2002: Selective Blockade of Drug-Induced Place Preference Conditioning by ACPC, a Functional NDMA-Receptor Antagonist., Neuropsychopharmacology, 27, p. 727, DOI: 10.1016/S0893-133X(02)00349-4 167 10.1016/S0893-133X(02)00349-4 false true Reference 69493638 /api/reference/69493638 168. Suzuki 2000: Effects of the Non-Competitive NMDA Receptor Antagonist Ketamine on Morphine-Induced Place Preference in Mice., Life Sci., 67, p. 383, DOI: 10.1016/S0024-3205(00)00639-1 168 10.1016/S0024-3205(00)00639-1 false true Reference 69493639 /api/reference/69493639 169. Popik 2003: Effects of Memantine, an NMDA Receptor Antagonist, on Place Preference Conditioned with Drug and Nondrug Reinforcers in Mice., Behav. Pharmacol., 14, p. 237, DOI: 10.1097/00008877-200305000-00008 169 10.1097/00008877-200305000-00008 false true Reference 69493640 /api/reference/69493640 170. Popik 1998: Inhibition of Reinforcing Effects of Morphine and Naloxone: Precipitated Opioid Withdrawal by Novel Glycine Site and Uncompetitive NMDA Receptor Antagonists., Neuropharmacology, 37, p. 1033, DOI: 10.1016/S0028-3908(98)00105-1 170 10.1016/S0028-3908(98)00105-1 false true Reference 69493641 /api/reference/69493641 171. Tzschentke 1995: N-Methyl-d-Aspartic Acid-Receptor Antagonists Block Morphine-Induced Conditioned Place Preference in Rats., Neurosci. Lett., 193, p. 37, DOI: 10.1016/0304-3940(95)11662-G 171 10.1016/0304-3940(95)11662-G false true Reference 69493642 /api/reference/69493642 172. LaLumiere 2008: Glutamate Release in the Nucleus Accumbens Core Is Necessary for Heroin Seeking., J. Neurosci., 28, p. 3170, DOI: 10.1523/JNEUROSCI.5129-07.2008 172 10.1523/JNEUROSCI.5129-07.2008 false true Reference 69493643 /api/reference/69493643 173. Eteraf-Oskouei, T., Mahmoudi Gharehbaba, A., Majidpour, S., and Asl, B.H. (2025). Preventive Effects of Crocin and Meloxicam on Morphine Withdrawal Symptoms in Mice: Behavioral and Biochemical Insights. BMC Pharmacol. Toxicol., 26., DOI: 10.1186/s40360-025-00999-9 173 10.1186/s40360-025-00999-9 false true Reference 69493644 /api/reference/69493644 174. Falls 1992: Extinction of Fear-Potentiated Startle: Blockade by Infusion of an NMDA Antagonist into the Amygdala., J. Neurosci., 12, p. 854, DOI: 10.1523/JNEUROSCI.12-03-00854.1992 174 10.1523/JNEUROSCI.12-03-00854.1992 false true Reference 69493645 /api/reference/69493645 175. Baker 1996: The NMDA Antagonist MK-801 Blocks the Extinction of Pavlovian Fear Conditioning., Behav. Neurosci., 110, p. 618, DOI: 10.1037/0735-7044.110.3.618 175 10.1037/0735-7044.110.3.618 false true Reference 69493646 /api/reference/69493646 176. Sugiyama 2019: Systemic Administration of a Delta Opioid Receptor Agonist, KNT-127, Facilitates Extinction Learning of Fear Memory in Rats., J. Pharmacol. Sci., 139, p. 174, DOI: 10.1016/j.jphs.2019.01.002 176 10.1016/j.jphs.2019.01.002 false true Reference 69493647 /api/reference/69493647 177. Ledgerwood 2003: Effects of D-Cycloserine on Extinction of Conditioned Freezing., Behav. Neurosci., 117, p. 341, DOI: 10.1037/0735-7044.117.2.341 177 10.1037/0735-7044.117.2.341 false true Reference 69493648 /api/reference/69493648 178. Walker 2002: Facilitation of Conditioned Fear Extinction by Systemic Administration or Intra-Amygdala Infusions of D-Cycloserine as Assessed with Fear-Potentiated Startle in Rats., J. Neurosci., 22, p. 2343, DOI: 10.1523/JNEUROSCI.22-06-02343.2002 178 10.1523/JNEUROSCI.22-06-02343.2002 false true Reference 69493649 /api/reference/69493649 179. Port 1998: Manipulation of NMDA-Receptor Activity Alters Extinction of an Instrumental Response in Rats., Physiol. Behav., 64, p. 391, DOI: 10.1016/S0031-9384(98)00095-X 179 10.1016/S0031-9384(98)00095-X false true Reference 69493650 /api/reference/69493650 180. Botreau 2006: D-Cycloserine Facilitates Extinction of a Cocaine-Induced Conditioned Place Preference., Behav. Brain Res., 172, p. 173, DOI: 10.1016/j.bbr.2006.05.012 180 10.1016/j.bbr.2006.05.012 false true Reference 69493651 /api/reference/69493651 181. Paolone 2009: The Facilitative Effects of D-Cycloserine on Extinction of a Cocaine-Induced Conditioned Place Preference Can Be Long Lasting and Resistant to Reinstatement., Psychopharmacology, 202, p. 403, DOI: 10.1007/s00213-008-1280-y 181 10.1007/s00213-008-1280-y false true Reference 69493652 /api/reference/69493652 182. Thanos 2009: D-Cycloserine Accelerates the Extinction of Cocaine-Induced Conditioned Place Preference in C57bL/c Mice., Behav. Brain Res., 199, p. 345, DOI: 10.1016/j.bbr.2008.12.025 182 10.1016/j.bbr.2008.12.025 false true Reference 69493653 /api/reference/69493653 183. Karel 2018: D-Cycloserine Enhanced Extinction of Cocaine-Induced Conditioned Place Preference Is Attenuated in Serotonin Transporter Knockout Rats., Addict. Biol., 23, p. 120, DOI: 10.1111/adb.12483 183 10.1111/adb.12483 false true Reference 69493654 /api/reference/69493654 184. Yang 2013: D-Cycloserine, Sarcosine and D-Serine Diminish the Expression of Cocaine-Induced Conditioned Place Preference., J. Psychopharmacol., 27, p. 550, DOI: 10.1177/0269881110388333 184 10.1177/0269881110388333 false true Reference 69493655 /api/reference/69493655 185. Myers 2010: D-Cycloserine Facilitates Extinction of Naloxone-Induced Conditioned Place Aversion in Morphine-Dependent Rats., Biol. Psychiatry, 67, p. 85, DOI: 10.1016/j.biopsych.2009.08.015 185 10.1016/j.biopsych.2009.08.015 false true Reference 69493656 /api/reference/69493656 186. Groblewski 2009: Effects of D-Cycloserine on Extinction and Reconditioning of Ethanol-Seeking Behavior in Mice., Alcohol. Clin. Exp. Res., 33, p. 772, DOI: 10.1111/j.1530-0277.2009.00895.x 186 10.1111/j.1530-0277.2009.00895.x false true Reference 69493657 /api/reference/69493657 187. Lu 2011: Effects of D-Cycloserine on Extinction and Reinstatement of Morphine-Induced Conditioned Place Preference., Neurosci. Lett., 503, p. 196, DOI: 10.1016/j.neulet.2011.08.034 187 10.1016/j.neulet.2011.08.034 false true Reference 69493658 /api/reference/69493658 188. Thanos 2011: D-Cycloserine Facilitates Extinction of Cocaine Self-Administration in Rats., Synapse, 65, p. 938, DOI: 10.1002/syn.20922 188 10.1002/syn.20922 false true Reference 69493659 /api/reference/69493659 189. Thanos 2011: D-Cycloserine Facilitates Extinction of Cocaine Self-Administration in C57 Mice., Synapse, 65, p. 1099, DOI: 10.1002/syn.20944 189 10.1002/syn.20944 false true Reference 69493660 /api/reference/69493660 190. 2006: Ionotropic and Metabotropic Glutamate Receptor Antagonism Attenuates Cue-Induced Cocaine Seeking., Neuropsychopharmacology, 31, p. 778, DOI: 10.1038/sj.npp.1300845 190 10.1038/sj.npp.1300845 false true Reference 69493661 /api/reference/69493661 191. 2004: Ionotropic Glutamate Receptor Antagonists Modulate Cue-Induced Reinstatement of Ethanol-Seeking Behavior., Alcohol. Clin. Exp. Res., 28, p. 558, DOI: 10.1097/01.ALC.0000122101.13164.21 191 10.1097/01.ALC.0000122101.13164.21 false true Reference 69493662 /api/reference/69493662 192. Lee 2009: D-Cycloserine Potentiates the Reconsolidation of Cocaine-Associated Memories., Learn. Mem., 16, p. 82, DOI: 10.1101/lm.1186609 192 10.1101/lm.1186609 false true Reference 69493663 /api/reference/69493663 193. Price 2009: D-Cycloserine and Cocaine Cue Reactivity: Preliminary Findings., Am. J. Drug Alcohol. Abus., 35, p. 434, DOI: 10.3109/00952990903384332 193 10.3109/00952990903384332 false true Reference 69493664 /api/reference/69493664 194. Prisciandaro 2015: D-Cycloserine Combined with Cue Exposure Therapy Fails to Attenuate Subjective and Physiological Craving in Cocaine Dependence., Am. J. Addict., 24, p. 217, DOI: 10.1111/ajad.12191 194 10.1111/ajad.12191 false true Reference 69493665 /api/reference/69493665 195. Price 2013: A Randomized, Placebo-Controlled Laboratory Study of the Effects of d-Cycloserine on Craving in Cocaine-Dependent Individuals., Psychopharmacology, 226, p. 739, DOI: 10.1007/s00213-011-2592-x 195 10.1007/s00213-011-2592-x false true Reference 69493666 /api/reference/69493666 196. Prisciandaro 2013: Impact of DCS-Facilitated Cue Exposure Therapy on Brain Activation to Cocaine Cues in Cocaine Dependence., Drug Alcohol Depend., 132, p. 195, DOI: 10.1016/j.drugalcdep.2013.02.009 196 10.1016/j.drugalcdep.2013.02.009 false true Reference 69493667 /api/reference/69493667 197. Pinard 2012: Inhibiting Glycine Transporter-1 Facilitates Cocaine-Cue Extinction and Attenuates Reacquisition of Cocaine-Seeking Behavior., Drug Alcohol Depend., 122, p. 119, DOI: 10.1016/j.drugalcdep.2011.09.017 197 10.1016/j.drugalcdep.2011.09.017 false true Reference 69493668 /api/reference/69493668 198. Uslaner 2010: Inhibition of Glycine Transporter 1 Attenuates Nicotine- but Not Food-Induced Cue-Potentiated Reinstatement for a Response Previously Paired with Sucrose., Behav. Brain Res., 207, p. 37, DOI: 10.1016/j.bbr.2009.09.035 198 10.1016/j.bbr.2009.09.035 false true Reference 69493669 /api/reference/69493669 199. Vengeliene 2018: Targeting Glycine Reuptake in Alcohol Seeking and Relapse., J. Pharmacol. Exp. Ther., 365, p. 202, DOI: 10.1124/jpet.117.244822 199 10.1124/jpet.117.244822 false true Reference 69493670 /api/reference/69493670 200. Cervo 2013: Inhibition of Glycine Transporter-1 Reduces Cue-Induced Nicotine-Seeking, but Does Not Promote Extinction of Conditioned Nicotine Cue Responding in the Rat., Addict. Biol., 18, p. 800, DOI: 10.1111/adb.12049 200 10.1111/adb.12049 false true Reference 69493671 /api/reference/69493671 201. Alasmari 2022: Interactive Role of Acid Sensing Ion Channels and Glutamatergic System in Opioid Dependence., Neurosci. Biobehav. Rev., 135, p. 104581, DOI: 10.1016/j.neubiorev.2022.104581 201 10.1016/j.neubiorev.2022.104581 false true Reference 69493672 /api/reference/69493672 202. Fuller, M.J., Andrys, N.R.R., Gupta, S.C., Ghobbeh, A., Kreple, C.J., Fan, R., Taugher-Hebl, R.J., Radley, J.J., Lalumiere, R.T., and Wemmie, J.A. (2024). The Role of Acid-Sensing Ion Channel 1A (ASIC1A) in the Behavioral and Synaptic Effects of Oxycodone and Other Opioids. Int. J. Mol. Sci., 25., DOI: 10.3390/ijms252111584 202 10.3390/ijms252111584 false true Reference 69493673 /api/reference/69493673 203. Knackstedt 2010: Ceftriaxone Restores Glutamate Homeostasis and Prevents Relapse to Cocaine Seeking., Biol. Psychiatry, 67, p. 81, DOI: 10.1016/j.biopsych.2009.07.018 203 10.1016/j.biopsych.2009.07.018 false true Reference 69493674 /api/reference/69493674 204. Raiteri 2003: Activation of a Glycine Transporter on Spinal Cord Neurons Causes Enhanced Glutamate Release in a Mouse Model of Amyotrophic Lateral Sclerosis., Br. J. Pharmacol., 138, p. 1021, DOI: 10.1038/sj.bjp.0705142 204 10.1038/sj.bjp.0705142 false true Reference 69493675 /api/reference/69493675 205. Aceto 2024: Glycine-Induced Activation of GPR158 Increases the Intrinsic Excitability of Medium Spiny Neurons in the Nucleus Accumbens., Cell. Mol. Life Sci., 81, p. 268, DOI: 10.1007/s00018-024-05260-w 205 10.1007/s00018-024-05260-w false true Reference 69493676 /api/reference/69493676 206. Wu 2017: Morphine-Induced Inhibition of Ca2+-Dependent d-Serine Release from Astrocytes Suppresses Excitability of GABAergic Neurons in the Nucleus Accumbens., Addict. Biol., 22, p. 1289, DOI: 10.1111/adb.12417 206 10.1111/adb.12417 false true Reference 69493677 /api/reference/69493677 207. Zafra 1995: Glycine Transporters Are Differentially Expressed among CNS Cells., J. Neurosci., 15, p. 3952, DOI: 10.1523/JNEUROSCI.15-05-03952.1995 207 10.1523/JNEUROSCI.15-05-03952.1995 false true Reference 69493678 /api/reference/69493678 208. Chieng 1998: Increased Opioid Inhibition of GABA Release in Nucleus Accumbens during Morphine Withdrawal., J. Neurosci., 18, p. 7033, DOI: 10.1523/JNEUROSCI.18-17-07033.1998 208 10.1523/JNEUROSCI.18-17-07033.1998 false true Reference 69493679 /api/reference/69493679 209. Reeves 2021: Mu Opioid Receptors on VGluT2-Expressing Glutamatergic Neurons Modulate Opioid Reward., Addict. Biol., 26, p. e12942, DOI: 10.1111/adb.12942 209 10.1111/adb.12942 false true Reference 69493680 /api/reference/69493680 210. Jin 2023: A2δ-1 Protein Drives Opioid-Induced Conditioned Reward and Synaptic NMDA Receptor Hyperactivity in the Nucleus Accumbens., J. Neurochem., 164, p. 143, DOI: 10.1111/jnc.15706 210 10.1111/jnc.15706 false true Reference 69493681 /api/reference/69493681 211. Suzuki 1999: Effects of the Non-Competitive NMDA Receptor Antagonist Ifenprodil on the Morphine-Induced Place Preference in Mice., Life Sci., 64, p. PL151, DOI: 10.1016/S0024-3205(99)00036-3 211 10.1016/S0024-3205(99)00036-3 false true Reference 69493682 /api/reference/69493682 212. Xu 2012: Essential Role of NR2B-Containing NMDA Receptor-ERK Pathway in Nucleus Accumbens Shell in Morphine-Associated Contextual Memory., Brain Res. Bull., 89, p. 22, DOI: 10.1016/j.brainresbull.2012.06.012 212 10.1016/j.brainresbull.2012.06.012 false true Reference 69493683 /api/reference/69493683 213. Oliva 2004: Neurochemical Changes of the Extracellular Concentrations of Glutamate and Aspartate in the Nucleus Accumbens of Rats after Chronic Administration of Morphine., Eur. J. Pharmacol., 483, p. 249, DOI: 10.1016/j.ejphar.2003.10.037 213 10.1016/j.ejphar.2003.10.037 false true Reference 69493684 /api/reference/69493684 214. Sepulveda 1998: Effect of Precipitated Withdrawal on Extracellular Glutamate and Aspartate in the Nucleus Accumbens of Chronically Morphine-Treated Rats: An in Vivo Microdialysis Study., Pharmacol. Biochem. Behav., 60, p. 255, DOI: 10.1016/S0091-3057(97)00550-9 214 10.1016/S0091-3057(97)00550-9 false true Reference 69493685 /api/reference/69493685 215. Kalivas 2009: The Glutamate Homeostasis Hypothesis of Addiction., Nat. Rev. Neurosci., 10, p. 561, DOI: 10.1038/nrn2515 215 10.1038/nrn2515 false true Reference 69493686 /api/reference/69493686 216. Alonso-Caraballo, Y., Li, Y., Constantino, N.J., Neal, M.A., Driscoll, G.S., Mavrikaki, M., Bolshakov, V.Y., and Chartoff, E.H. (2024). Sex-Specific Behavioral and Thalamo-Accumbal Circuit Adaptations after Oxycodone Abstinence. bioRxiv., DOI: 10.1101/2024.08.01.605459 216 10.1101/2024.08.01.605459 false true Reference 69493687 /api/reference/69493687 217. Zhang 2020: Mu-Opioid Receptors Expressed in Glutamatergic Neurons Are Essential for Morphine Withdrawal., Neurosci. Bull., 36, p. 1095, DOI: 10.1007/s12264-020-00515-5 217 10.1007/s12264-020-00515-5 false true Reference 69493688 /api/reference/69493688 218. McDevitt 2024: The Paraventricular Thalamic Nucleus and Its Projections in Regulating Reward and Context Associations., eNeuro, 11, p. 1, DOI: 10.1523/ENEURO.0524-23.2024 218 10.1523/ENEURO.0524-23.2024 false true Reference 69493689 /api/reference/69493689 219. Won 2023: Mapping Astrocytic and Neuronal μ-Opioid Receptor Expression in Various Brain Regions Using MOR-MCherry Reporter Mouse., Exp. Neurobiol., 32, p. 395, DOI: 10.5607/en23039 219 10.5607/en23039 false true /api/publication/36410412 Essmat Nariman et al. Crosstalk Between Glycinergic and N-Methyl-D-Aspartate Receptor-Mediated Glutamatergic Transmission in Behaviours Associated with Opioid Use Disorder. (2025) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 26 21<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10090082"><a href="/gui2/?type=authors&mode=browse&sel=10090082" target="_blank">Essmat Nariman (<span class="authorship-author-name">Gomaa Nariman Essmat Mohamed Abdeltawab</span> <span class="authorAux-mtmt"> In vivo and in vitro pain assessment</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10096971"><a href="/gui2/?type=authors&mode=browse&sel=10096971" target="_blank">Boldizsár Imre Jr.^* (<span class="authorship-author-name">Boldizsár Jr Imre</span> <span class="authorAux-mtmt"> farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10101816"><a href="/gui2/?type=authors&mode=browse&sel=10101816" target="_blank">Chalabiani Yashar (<span class="authorship-author-name">Chalabiani Yashar</span> <span class="authorAux-mtmt"> neuropsychopharmacology</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10075565"><a href="/gui2/?type=authors&mode=browse&sel=10075565" target="_blank">Varga Bence Tamás (<span class="authorship-author-name">Varga Bence Tamás</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10090125"><a href="/gui2/?type=authors&mode=browse&sel=10090125" target="_blank">Abbood Sarah Kadhim (<span class="authorship-author-name">Abbood Sarah Kadhim</span> <span class="authorAux-mtmt"> In vivo AND In vitro pain assessment</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10101715"><a href="/gui2/?type=authors&mode=browse&sel=10101715" target="_blank">Kirchlechner-Farkas Judit Mária (<span class="authorship-author-name">Kirchlechner-Farkas Judit Mária</span> <span class="authorAux-mtmt"> famakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015480"><a href="/gui2/?type=authors&mode=browse&sel=10015480" target="_blank">Király Kornél (<span class="authorship-author-name">Király Kornél P</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10011448"><a href="/gui2/?type=authors&mode=browse&sel=10011448" target="_blank">Miklya Ildikó (<span class="authorship-author-name">Miklya Ildikó</span> <span class="authorAux-mtmt"> Neuropszichofarmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10009109"><a href="/gui2/?type=authors&mode=browse&sel=10009109" target="_blank">Gyertyán István (<span class="authorship-author-name">Gyertyán István</span> <span class="authorAux-mtmt"> Viselkedésfarmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10012548"><a href="/gui2/?type=authors&mode=browse&sel=10012548" target="_blank">Tábi Tamás (<span class="authorship-author-name">Tábi Tamás</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Gyógyszerésztudományi Kar">GYTK</span>/Gyógyszerhatástani Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10005121"><a href="/gui2/?type=authors&mode=browse&sel=10005121" target="_blank">Fürst Susanna (<span class="authorship-author-name">Fürst Zsuzsanna</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10000022"><a href="/gui2/?type=authors&mode=browse&sel=10000022" target="_blank">Harsing Laszlo G. (<span class="authorship-author-name">Hársing László Gábor</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10031135"><a href="/gui2/?type=authors&mode=browse&sel=10031135" target="_blank">Zádor Ferenc (<span class="authorship-author-name">Zádor Ferenc</span> <span class="authorAux-mtmt"> Opioid receptorok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10015484"><a href="/gui2/?type=authors&mode=browse&sel=10015484" target="_blank">Al-Khrasani Mahmoud ✉ (<span class="authorship-author-name">Al-Khrasani Mahmoud</span> <span class="authorAux-mtmt"> Farmakológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Farmakológiai és Farmakoterápiás Intézet; <span title="Semmelweis Egyetem">SE</span>/<span title="Központi Szervezeti Egységek (beleértve az Egyéb Szervezeti Egységeket)">KSZE</span>/Farmakológiai és Gyógyszerkutatás-fejlesztési Központ</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;36410412" target="_blank">Crosstalk Between Glycinergic and N-Methyl-D-Aspartate Receptor-Mediated Glutamatergic Transmission in Behaviours Associated with Opioid Use Disorder</a></div> <div> <span class="journal-title">INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1661-6596">1661-6596</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1422-0067">1422-0067</a>)</span>: <span class="journal-volume">26</span> <span class="journal-issue">21</span> <span class="page"> Paper 10526. 34 p. </span> <span class="year">(2025)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3390/ijms262110526" target="_blank" href="https://doi.org/10.3390/ijms262110526"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="001612716300001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/001612716300001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="105021632191" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-105021632191"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="41226576" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41226576&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Inorganic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Spectroscopy&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Catalysis&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Computer Science Applications&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Physical and Theoretical Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Molecular Biology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q2</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 1</span> | Független: 1 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 1 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;1 | DOI jelölt:&nbsp;1 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;36410412&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 8 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 36410412</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Összefoglaló cikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">WOS TAGGED</span> </div> <div class="funder"> (FK_138389), (TKP2021-EGA-25), (Semmelweis 250+ Kiválósági PhD Ösztöndíj), (2024-2.1.1-EKÖP) </div> <div class="lastModified">Utolsó módosítás: 2026.07.10. 09:30 Gere Tamásné (SE_KK_Admin5_GT, admin) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Essmat, N. and Boldizsár, I., Jr. authors contributed equally to this work.</pre> </div></div>